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A B S T R A C T
Alternative polyadenylation (APA) is now widely recognized to regulate gene expression. APA is an RNA-pro-
cessing mechanism that generates distinct 3′ termini on mRNAs, producing mRNA isoforms. Different factors
influence the initiation and development of this process. CFIm25 (among others) is a cleavage and poly-
adenylation factor that plays a key role in the regulation of APA. Shortening of the 3′UTRs on mRNAs leads to
enhanced cellular proliferation and tumorigenicity. One reason may be the up-regulation of growth promoting
factors, such as Cyclin D1. Different studies have reported a dual role of CFIm25 in cancer (both oncogenic and
tumor suppressor). microRNAs (miRNAs) may be involved in CFIm25 function as well as competing endogenous
RNAs (ceRNAs). The present review focuses on the role of CFIm25 in cancer, cancer treatment, and possible
involvement in other human diseases. We highlight the involvement of miRNAs and ceRNAs in the function of
CFIm25 to affect gene expression. The lack of understanding of the mechanisms and regulation of CFIm25 and
APA has underscored the need for further research regarding their role in cancer and other diseases.
1. Introduction
It is known that dynamic regulation mechanisms under diverse
physiological conditions affects the processing and maturation of
mRNAs in eukaryotic cells. Polyadenylation involves the attachment of
a poly(A) tail to the 3′untranslated regions (UTR) of messenger RNAs
(mRNA) promoting stability, enabling efficient nuclear export and
translation [13,23,44,82]. Polyadenylation in mammals includes six
primary protein complexes: (a) cleavage and polyadenylation specifi-
city factor (CPSF); (b) cleavage stimulatory factor (CSTF); (c) cleavage
factors I and II (CFIm and CFIIm); (d) poly(A) polymerase; (e) poly(A)
binding protein; (f) RNA polymerase II and additional proteins [49,67].
Alternative polyadenylation (APA) is a process that produces mRNA
isoforms that differ only in their 3′-UTRs [74]. APA can result from the
presence of multiple polyadenylation sites or mutually exclusive
terminal exons. APA can cause differential expression of mRNA tran-
scripts by influencing their stability, export to the cytoplasm, and
translation efficiency. One of the major factors that governs APA was
found to be CF1m [47]. CFIm is a heterodimer consisting of CFIm25
and either of two closely related subunits, CFIm68 or CFIm59.
CFIm is one of the strongly conserved components of eukaryotic
mRNA 3′ processing machinery, which acts in a sequence-specific poly
(A) location via two collaborating protein sub-units: a 25 kDa sub-unit
consisting of a nudix domain (CFIm25), and a larger sub-unit which can
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be 59, 68, or 72 kDa (CFIm59, CFIm68, or CFIm72) with a RNA re-
cognition motif (RRM). Prior research has shown CFIm25 is necessary
and sufficient to bind sequences specific for the poly(A)-site up-stream
component UGUA [87]. Yang and colleagues demonstrated the crys-
talline structures of CFIm25 complexed with RRM domains of RNA and
CFIm68 [86]. Binding in the CFIm25 dimer can take place at opposite
sides through two CFIm68 RRM domains. All CFIm25 sub-units speci-
fically bind a single UGUA component. Biochemical analysis indicates
that stronger RNA binding and easier RNA looping are provided by the
CFIm68 RRMs. The inherent property of CFIm to direct RNA looping
can offer an explanation for its ability to regulate the choice of alter-
native poly(A) attachment sites [86].
CFIm25 can function as a tumor inhibitor or as an oncogene under
various conditions [54].
In glioblastoma, down-regulation of CFIm25 led to the enhancement
of tumorigenic properties and increased tumor size. On the other hand,
over-expression of CFIm25 led to reduction in these properties and
impeded tumor growth [47]. A subset of CFIm25-regulated genes with
shortened 3′UTRs due to APA were found in various tumors with re-
duced expression of CFIm25. Despite the connection between CFIm25
and tumorigenicity found in this study, more research is needed to fully
elucidate the role of CFIm25 in cancer. Some other studies have sug-
gested that the over-expression of CFIm25 is associated with tumor-
igenesis.
Lou et al., found that there was a significant up-regulation CFIm25
in human glioma tissues and also that CFIm25 seems to induce pro-
liferation of glioma cells, likely via the NF-κB signaling pathway [42].
Their results revealed that CFIm25 is an upstream modulator of the NF-
κB pathway and could be a potential molecular marker for the me-
senchymal subtype of GBM [42].
In another study, Zhang et al., found there was a significant increase
in the expression of CFIm25 in subjects with primary chronic myelo-
cytic leukemia, and in K562 leukemic cells at the mRNA level in
comparison to a healthy group and in PBMCs [89]. Their results sug-
gested that down-regulation of CFIm25 could inhibit the proliferation,
and induce apoptosis in K562 cells. Pathway analysis showed that the
MAPK/ERK pathway is a crucial molecular mechanism underlying the
effects of CFIm25 knockdown in K562 cells [89].
The dual functions of CFIm25 may be due to the utilization of
samples from different sources or tumors at different stages, thus
making the true role of this gene uncertain.
2. Alternative polyadenylation
Studies have investigated the impact of the dynamic adjustment in
different physiological situations in which APA takes place at the
3′UTRs of mRNAs [44,48]. More than 50% of the genes in humans,
possess several poly-adenylation sites that result in an increased variety
of mRNA transcript lengths [73]. Through such different poly(A) sites
(PAS), APA may be used to produce mRNA isoforms. Various uses of
alternative PAS situated in the same terminal exon is the commonest
form of APA [9]. Negative regulation components, which decrease
stability of mRNA or impair the translation efficacy, including AU-rich
elements (AREs), and miRNAs may be inhibited via processing on the
most proximal PAS [64,84]. Expression of mRNAs containing shorter
3′UTRs is up-regulated in rapidly proliferating cells and in transformed
cells [5,11,68]. However, there are still unknown mechanisms, which
are concerned with the shifting of PAS from distal to proximal sites that
is found in proliferating and or transformed cells, the cause and effect
relationships, and important target genes that are dependent on such
regulation (Fig. 1).
One of the classes of these post-transcriptional regulatory molecules
is RNA binding proteins (RBPs). Increasing evidence shows that RBPs
may be dysfunctional in cancer genomes [21]. Findings have demon-
strated that RBPs are crucial players in APA. For instance, the modified
expression of RBPs in the brain of Huntington's disease (HD) patients
can result in alterations in the expression of mRNA 3′UTR iso-forms
[62]. There can be interactions between RBPs and nascent mRNA
during the processes of APA and transcription that lead to modifications
in the choice of polyA location, and the isoforms produced. For ex-
ample, aberrant expression of the 3′ end regulatory factors can result in
multiple alterations in isoforms [15]. Romo and colleagues reported
that distinct expression of three 3′-end processing proteins was found in
HD grade 1 motor cortex: PCBP2, THOC5, CPSF2 [62]. It is possible that
RBPs bind post-transcriptionally to the isoforms, which thus influences
isoform stability and decay, resulting in modification of the isoform
abundance. Researchers have found a relationship between lower
CNOT6 deadenylase and less HTT long isoform; however, short or mid-
length isoforms did not change. Additional research is crucial to de-
termine the mechanisms of 3′UTR isoform alterations in HD. One study
demonstrated that the amounts of HTT and SECISBP2L isoform re-
sponded to modifications in the levels of CNOT6 mRNA. Nonetheless,
not all the isoform changes discussed in the present study can be ex-
plained by the modified expression of CNOT6 in HD. The rest of the
RNA binding proteins, including 3′ end processing factors probably
influence the isoform abundance in HD. New treatment approaches for
HD may be achieved by discovering reasons for the isoform modifica-
tions in the HD motor cortex [62].
The consequences of APA for gene expression and cell function are
becoming steadily clearer, as this is an active area of research. The
understanding of the mechanisms that regulate APA is of high im-
portance, and an increasing number of APA-regulatory factors have
been identified and characterized [44].
3. CFIm25 as a tumor suppressor in cancer
CFIm25 has been shown to have tumor suppressive properties.
Several studies have investigated the effects of CFIm25 protein and the
NUDT21 gene (which encodes CFIm25) in tumor cells, and various
molecules and signaling pathways have been explored. The MAPK
pathway is an important signaling pathway involved in proliferation
and metastasis of tumors [54]. A recent study reported that CFIm25
knockdown led to an increase in phosphorylated JNK, p53, and c-Jun in
hepatocellular carcinoma cells (HCCs). It was shown that the c-Jun-
driven activating protein-1 (AP-1), a downstream effector of c-Jun, was
activated by inhibition of CFIm25. In addition, regulation of the p38
and JNK/c-Jun pathways by CFIm25 resulted in increased expression of
E-cadherin in these cells [78]. According to recent findings, CFIm25
may be involved in the process of tumor metastasis. EMT is an im-
portant stage required for tumor metastasis, and E-cadherin is the main
mediator of cell-to-cell adhesion junctions in epithelial tissues [34].
Research has shown that inhibition of E-cadherin leads to adoption of
mesenchymal cell morphology, and increased invasion and metastasis
[25]. EMT is a dynamic and reversible process, which switches between
the epithelial and mesenchymal phenotypes during tissue growth and
healing [75]. The EMT leads to switching of epithelial cells with tight
junctions into fibroblast-like cells with looser junctions [65]. Results
indicated that re-expression of E-cadherin in cell lines, in which it has
been depleted, can reverse the poorly-differentiated malignant pheno-
type with fibroblastic morphology. This reduces the invasiveness, and
leads to a more differentiated epithelioid phenotype with tighter cell-to-
cell junctions [61]. Depleting E-cadherin activates oncogenic signaling
pathways such as MAPK, rat sarcoma viral oncogene (Ras), Ras-related
C3 botulinum toxin substrate (Rac1), and disrupts the Hippo signaling
pathway all of which are involved in cancer cell migration and invasion
[25]. Findings have demonstrated that the expression of E-cadherin is
reduced with higher expression of CFIm25 and vice versa. Interestingly,
changes in the expression of N-cadherin move in opposite directions to
those of E-cadherin. Results have suggested that metastasis of tumors
such as HCC could be prevented by CFIm25 through suppression of the
EMT [25].
Sheng Tan et al. [71] showed that the expression of CFIm25 gene
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was decreased in HCC tissue, as well as that lower CFIm25 expression
was related to shorter survival-time in patients with HCC after surgery.
They also reported that knockdown of CFIm25 led to HCC cellular
proliferation, HCC development and metastasis. They suggested that
the tumor suppressive effects of CFIm25 may be related to its regulatory
function on the PSMB2 and CXXC5 genes. PSMB2 is one subunit of a
multi-catalytic proteinase complex that contains a well-ordered ring-
like 20S core structure [7]. Even though proteasomes are considered to
Fig. 1. Alternative polyadenylation. (A) 3′-End processing complexes and cis-acting elements of the 3′-terminal exon for polyadenylation. There is an association
between RNA polymerase II C-terminal domain (CTD) with 3′-end processing proteins. To determine the cleavage site of a transcript during termination of tran-
scription, a combination of upstream sequence elements (USE), downstream sequence elements (DSE), and polyadenylation sites (PAS) are used. (B) Alternative
polyadenylation (APA) and its impact on protein production. In 3′-untranslated region (UTR) APA, an increase in proximal PAS is possible by cleavage stimulation
factor 2 (CSFT2) and a decrease in proximal PAS is possible by cleavage and polyadenylation specificity factor 5/6 (CPSF5/6). The interaction with miRNAs or RNA-
binding proteins (RBPs) and modulation of protein synthesis could be influenced by the length of 3′-UTR. In intron regions, the coding capacity of protein and thus
truncated protein production could be influenced by APA. CF, cleavage factor; PCF11, PCF11 cleavage and polyadenylation factor subunit; CLP1, cleavage and
polyadenylation factor I subunit 1; WDR33, WD repeat domain 33; FIP1L1, factor interacting with PAPOLA and CPSF1; ATG, initiation codon; TAA, termination
codon; TSS, transcription start site.
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be treatment targets in several types of cancer, the contribution of
PSMB2 has not been confirmed. In addition, reports have indicated that
over-expression of CXXC5 is an undesirable prognostic factor in solid
tumors including breast cancer [27]. However, there have been few
studies on the contribution of CXXC5 to HCC. Knockdown of CFIm25
resulted in a significantly increased expression of these genes. In ad-
dition, knockdown of PSMB2 and CXXC5 inhibited HCC cell invasion
and proliferation.
Another study investigated the role of CFIm25 expression in glioma
cell proliferation. This study showed that increased expression of
CFIm25 induced glioma cell proliferation by regulation of NF-kB sig-
naling pathway. CFIm25 regulated NF-kB inhibitor zeta (NFKBIZ)
which is a downstream target for this gene [43]. Further evidence has
shown that decreased expression of CFIm25 in glioblastoma cells pro-
moted tumorigenic features as well as increased tumor size [47]. These
findings suggested that CFIm25 could inhibit glioblastoma growth,
possibly by mediating the repression of APA-dependent shortening of
mRNA 3′UTRs. This study identified CFIm25 (among fifteen different
poly-adenylation and cleavage factors) to be one of the most important
factors that governs the broad regulation of APA. It was important to
provide insight into how APA modulates genes by large-scale short-
ening of 3′UTRs, resulting in increased cell growth and tumorigenicity
by enhancing growth factors, including cyclin D1. Conversely, in-
creased expression of CFIm25 inhibited these oncogenic traits. Thus,
these findings clarified the suppressive role of CFIm25 in the initiation
and progression of glioblastoma tumors [17,47]. Moreover, the findings
illustrated the significance of 3′UTRs in controlling the growth of cells,
and emphasized the necessity of additional studies on APA and its po-
tential relationships with other human diseases [47].
In the testis, planar division of undifferentiated germ cells is an
important event, which when disrupted leads to testicular atrophy and
low fertility, as well as the development of testicular germ cell tumors.
Planar cell division of germ cells is regulated by the spindle-associated
RHAMM. The expression of RHAMM is also regulated by CFIm25.
Huaibiao Li et al. investigated the role of CFIm25 in regulation of
RHAMM expression. They observed that CFIm25 up-regulated RHAMM
expression. Therefore, they concluded that impairment in expression of
CFIm25 led to decreased expression of RHAMM creating testicular
atrophy and low fertility, which are related to initiation and promotion
of testicular germ cell tumors [37]. Recent studies have investigated the
relationship between gene expression profiles and chemotherapy drug
resistance. In leukemic cells, transcriptome profiling showed that the
CFIm25 gene had the best correlation with resistance to etoposide.
These findings suggested that this gene could be useful to evaluate the
sensitivity to some drugs, which are used in chemotherapy [69,70]. The
possible mechanism of the effect of CFIm25 on leukemia cells was as-
sessed in another study [89]. In this study silencing of the CFIm25 gene
led to inhibition of the proliferation and induction of apoptosis in
K562 cells. It was also observed that CFIm25 regulated p-ERK expres-
sion, and subsequently enhanced K562 proliferation. These results
showed that the MAPK/ERK signaling pathway may be a mechanism
affected by CFIm25. Reports have suggested there is a strong relation-
ship between the ERK pathway and rapid growth and apoptosis of cells.
The rapid growth of K562 cells and reduction of apoptosis in vitro, have
been confirmed using agonists of the ERK pathway. PTEN is a classic
inhibitor of the ERK pathway. qRT-PCR and Western blot analysis re-
vealed there was significant up-regulation of PTEN expression after
NUDT21 knockdown. It should be noted that PTEN contributes to the
phosphorylation of ERK1/2 and tumorigenesis. Results confirmed that
rapid growth and reduced apoptosis of leukemia cells were caused by
NUDT21 knockdown, via up-regulation of PTEN. Nonetheless, it is
possible that other pathways besides PTEN and ERK are also engaged.
These results emphasized the necessity of additional studies to explore
the mechanisms of suppression of proliferation and increased apoptosis
in K562 cells after NUDT21 knockdown. Collectively, these findings
suggest that CFIm25 and its encoding gene, NUDT21, have tumor-Ta
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suppressive properties, which may provide a novel therapeutic strategy
for cancer [89]. Table 1 lists studies of CFIm25 as a tumor suppressor in
different malignancies (see Table 2).
4. CFIm25 and microRNAs
Only a small part (∼1.5%) of the genetic material in the human
genome is involved in coding proteins, yet most non-coding genomic
DNA is still involved in the regulation of gene expression [32]. In
particular, gene expression has two levels of regulation: transcriptional
regulation controls gene transcription and its extent, while post-tran-
scriptional regulation affects the transcribed RNA molecules, including
their stability, translation efficiency and subcellular localization [50].
Several multi-component cellular mechanisms are involved in reg-
ulating each level. Each one of these mechanisms carries out a separate
step in gene expression regulation. Gene expression regulators, rather
than working as a simple linear assembly line, couple together to form a
complex network. These networks coordinate their activities, thus
maximizing the efficiency and specificity of each step in gene expres-
sion [31]. In recent years, post-transcriptional gene regulation has at-
tracted more attention in mammalian organisms. Using processing steps
such as alternative splicing or APA, the same primary transcript can
generate a number of different mRNA isoforms [73,77]. Today, new
classes of non-coding RNA genes, including the abundant and con-
served family of miRNAs, have been identified [41,60]. APA often
creates mRNA 3′ UTRs with different lengths, and miRNAs, by binding
to specific mRNA 3′ UTRs, regulate gene expression (Fig. 2). The as-
sociation between APA and nonsense-mediated RNA decay (NMD) has
been discussed in previous studies. NMD is a mRNA surveillance me-
chanisms that eliminates mRNAs containing a premature stop codon
[10,36,40,55,76]. It is logical that there should be an interplay between
APA and miRNA-mediated mRNA decay. The COX2 gene in colorectal
cancer cells shows this property. The 2.6-kb isoform of COX-2 mRNA
lacking the miR-101/miR-199a target of the 3′ UTR, rather than 4.5-kb
isoform, was selectively stabilized in growing cells. Accordingly, it can
be concluded that in cancer cells, COX2 mRNA may escape regulation
through the usage of alternative PAS. A shift in expression of proximal
PAS isoforms may lead to the avoidance of regulation by miRNAs,
causing enhanced proliferation and unrestricted cell cycle progression
(40). This is consistent with the fact that miRNAs influence many as-
pects of cellular proliferation and the cell cycle progression. Accord-
ingly, down-regulation of miRNAs expression increases cellular trans-
formation and tumorigenesis. This phenomenon has been observed in
many different cancer cells [2,12,24] (Fig. 2). Over the course of evo-
lutionary selection, changes in the length of the 3′ UTRs has led to many
genes reducing their miRNA binding sites [1]. An increased level of
COX2 protein has been observed both in human and animal colorectal
tumors. Nevertheless, the normal intestinal mucosa displays low to
undetectable levels of COX2 expression [30]. Similarly, an increased
level of COX2 resulting from defects in its regulation, has been reported
in many other solid tumors, including breast, lung, prostate, pancreas,
bladder, stomach, esophagus and head and neck cancers [4,59,83].
Therefore, it is reasonable to suppose that an interplay between APA in
COX2 and regulation by miR-101/miR-199a, at least to some extent,
may contribute to the development of cancer.
Physiological conditions finely regulate the expression of the PTEN
(phosphatase and tensin homolog) gene by transcriptional and post-
transcriptional mechanisms. The PTEN gene is one of the most fre-
quently mutated genes in cancers [39]. The changes in PTEN expres-
sion, even if modest, have a significant influence on tumorigenesis and
tumor progression in mouse models [3]. Loss of a single copy of PTEN in
some body organs, like prostate, lung, breast and colon can lead to
oncogenic consequences. The remaining copy of PTEN is typically re-
tained until the development of more aggressive and metastatic tumors
[38,57]. Thivierge et al. showed that APA leads to an important di-
versity of co-expressed PTEN 3′-UTR mRNA isoforms. They also sug-
gested that the relative expression of PTEN 3′-UTR mRNA isoforms is
dynamically controlled by the cell density [72]. The findings of their
study showed that, despite encoding a diversity of validated miRNA-
binding sites, longer 3′-UTRs were largely refractory to miRNA-medi-
ated silencing, and accounted for the bulk of PTEN protein expression.
Four lines of evidence support this finding. Firstly, no response to in-
hibition or over-expression of miRNAs, whether endogenous or ex-
pressed from reporter constructs, was observed in long PTEN 3′-UTR
isoforms. In addition, a potent response was observed in reporters en-
coding 3X miRNA-binding sites. Secondly, the long 3′-UTR isoforms, in
comparison with the shorter 300 nt isoform, were significantly more
stable. Accordingly, they encode fewer miRNA-binding sites. Thirdly,
despite the co-expression of the shorter 3′-UTR isoforms, the rate of
knockdown of longer PTEN 3′-UTR mRNA isoforms and the changes in
PTEN protein were closely correlated. Fourthly, upon specific knock-
down of longer PTEN 3′-UTR isoforms, activation of PI3K/Akt/mTOR
signaling was observed. This occurred while the shorter PTEN 3′-UTR
isoforms were still expressed. Therefore, it can be concluded that
shorter PTEN 3′-UTR isoforms cannot compensate for the loss of longer
3′-UTR isoform mRNAs, whether functionally or affecting the overall
PTEN protein load [72].
According to Hinske et al., APA is a possible mechanism that gov-
erns the negative feedback exerted by intronic miRNA on their host
genes [18]. The findings of their study also showed that the host genes
that contain matching sites for their intronic miRNAs will have longer
3′UTRs with more polyadenylation sites. In addition, a significant dif-
ference was observed between the expression of these host genes and
the host genes of miRNAs lacking potential miRNA binding sites. Then,
in order to investigate the relationship between ZFR (zinc finger RNA
binding protein) and its intronic miRNA miR-579, they carried out in-
silico modeling, and used the U87 cell line as a biological model. They
showed that ZFR was targeted by its intronic miRNA, which allowed
differential targeting due to APA.
In this study, bioinformatics analysis and RNA-Seq were used to
evaluate the potential cross-talk between intronic miRNAs and APA.
The findings showed that CPSF2, a gene previously associated with APA
signal recognition, might alter the polyadenylation signal which is as-
sociated with negative feedback by intronic miRNA [18].
Previous studies showed that miR-181a was increased in osteo-
sarcoma, and enhanced the proliferation and suppressed apoptosis in
Table 2
Effects of CFIm25 in non-cancerous diseases.
Ref Function (s) Target (s) Disease
[52,53,80] Increase the levels of fibronectin and collagen I in pulmonary fibrosis Fibronection, collagen 1 Idiopathic Pulmonary Fibrosis
[45] Induce proliferation CCND1 B-cell malignancy mantle cell lymphoma
(MCL)
[28,29] Up-regulation of miR-203 Profibric and matrix gene Idiopathic fibrosis (IPF)
[8,79] Remodeling of pulmonary arteries ECM component, TGF-β and the
Wnt pathways
Pulmonaryhypertention (PH)
[14] Increase usage of the distal polyadenylation site in the MECP2 3′ UTR which
results in an enrichment in inefficiently translated long mRNA isoforms
MECP2 Neuropsychiatric disease
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osteosarcoma cells. Accordingly, a recent study evaluated the re-
lationship between miR-181a and CFIm25 expression. The results of
this study showed that miR-181a and down-regulated CFIm25 expres-
sion led to increased cell proliferation and inhibition of apoptosis in
these cells [90]. Over-expression of CFIm25 inhibited the rapid growth,
enhanced apoptosis, and suppressed the expression of cyclin D1 in os-
teosarcoma cells. Moreover, they showed that silencing of miR-181a in
osteosarcoma cells was induced by expression of CFIm25 protein [90].
The molecular mechanism responsible for growth inhibition and
apoptosis of osteosarcoma may involve silencing miR-181a via re-
storation of CFIm25. It is possible that the inhibition of miR-181a could
be a treatment strategy for restoration of CFIm25-mediated function.
However it will be necessary to confirm the connection between
CFIm25 and miR-181a using in-vivo experiments in animal models.
5. miRNA as an important mediator in CFIm25 function
APA sites are found in most mammalian genes, and lead to variation
in the 3′UTR lengths [20,56,85]. CFIm25 apparently prevents break-
down of the proximal PAS by CPSF, because lack of this protein inside
the cell leads to shortening of the 3′-UTR, as well as the lack of several
miRNA regulatory elements (MRE) (58). The fate of the mRNA is as-
sociated with changes in the length of 3′ UTRs. The reason could be
altered binding between RBPs and miRNAs. Proliferating cells have
more APA sites, which in turn results in shorter 3′UTRs. Such short-
ening prevents mRNAs from being targeted by miRNAs whose binding
sites are eliminated (Fig. 3). For example, proliferating T cells have
significantly shorter 3′ UTRs compared to resting T-cells, which could
be due to having fewer binding sites for miR-155 and miR-17-92.
Cancer cells express mRNAs with overall shorter 3′ UTRs. Due to the
escape from miRNA regulation, this shortening has been linked to the
activation of oncogenes [51]. The same mechanism, although with
different details, accounts for the shortening of 3′UTRs in oncogenes
and tumor suppressor genes. miR-23 can down-regulate the shortened
KGA (kidney glutaminase) 3′UTR, although it only slightly affects the
full-length KGA 3′UTR, GAC (C-terminal truncated splice variant, or
glutaminase C) is subject to repression by miR-23 [46].
The ceRNA network is another mechanism for regulation of gene
expression. According to the theory of ceRNA regulation, pseudo-genes
and non-coding RNAs share MREs with coding genes. Hence, miRNAs
and MREs are considered the main operators and regulators of ceRNA,
respectively [63]. Therefore, the greater the number of pseudo-genes
for a single gene, that gene will also have a greater number of MRE.
Also, the competition between miRNAs to target transcripts with a
common MRE leads to an increase in overall gene expression. The effect
of the ceRNA network on the 3′UTR shortened mRNAs coding for tumor
suppressor genes (a total decrease in the number of MREs), reduces the
number of copies of the tumor suppressor gene by an increased silen-
cing by miRNA. For example, in EPS15 (epidermal growth factor re-
ceptor substrate 15), the overlap between 4 miRNA binding sites and
the tumor suppressor PTEN, combined with 3′UTR shortening resulted
in loss of the miRNA sites, and consequently prevented it from com-
peting with PTEN miRNAs, silencing the PTEN. For tumor suppressor
genes, but not oncogenes, 3′ UTR shortening ceRNA hub genes were
enriched, showing that 3′ UTR shortening represses tumor suppressor
genes in trans. CFIm25 repressed tumor suppressor genes including
PHF6 (plant homeodomain-like finger 6) and LARP1 (la ribonucleo-
protein domain 1) in trans in a miRNA-dependent manner [58]. In the
miR17-92 cluster, the binding sites which are up-regulated in rapidly
proliferating cells, are particularly enriched just upstream to the APA
sites. This probably provides them with stronger inhibitory activity
upon shortening. Therefore, 3′UTR shortening both enables escape from
inhibition of growth promoting genes, and potentiates repression of
anti-proliferative genes [19].
6. Role of CFIm25 in non-cancerous diseases
Several roles of CFIm25 have also been investigated in other dis-
eases and pathological states. APA is an important process in the ex-
pression of fibrotic proteins and extra cellular matrix components. It
has been shown that CFIm25, (a key factor of APA), is decreased in the
lungs of patients and in mice with pulmonary fibrosis, leading to ele-
vation of expression of fibronectin, alpha smooth muscle cell actin and
collagen I (all markers for pulmonary fibrosis) and therefore CFIm25
Fig. 2. Different regulatory impacts of miRNAs on longer and shorter isoforms of mRNA which cause cellular proliferation and cancer.
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may be involved in the development of this disease. These findings
suggest that CFIm25 and APA may combine to result in the production
of excessive amounts of ECM proteins [52,53,80].
Some studies have demonstrated that the down-regulation of
CFIm25 in fibroblasts of pulmonary fibrosis patients and in mice is
related to the TGF-β signaling pathway. It has been found that ex-
pression of TGF-β1 (a pro-fibrotic cytokine) reduced the expression of
CFIm25 in lung fibroblasts via activation of the mTOR pathway,
therefore, leading to the development and progression of idiopathic
pulmonary fibrosis (IPF). Prevention of the reduction of CFIm25 by
rapamycin (a mTOR inhibitor) supported the previous results [28,29].
Weng and colleagues investigated whether APA was involved in IPF.
The researchers demonstrated reduced levels of CFIm components
(CPSF59, CFIm25, & CPSF68) in myo-fibroblasts isolated from the lungs
of patients with IPF, and also in mice with pulmonary fibrosis. This
finding indicated that 3′-UTR shortening was involved in the differ-
entiation process of fibroblasts into myofibroblasts [81]. Additionally,
downregulation of CFIm25 can lead to shortening of the 3′-UTRs of
profibrotic genes, including Tgfbr1 and Col1a1, and enhancement of the
major intermediates in numerous pro-fibrotic pathways. Furthermore,
the authors produced pulmonary fibrosis in mice by exposing them to
bleomycin, and found that CFIm25 was depleted in lung fibroblasts.
This showed that the down-regulation of CFIm25 and increased APA
played a role in the pathogenesis of pulmonary fibrosis. It should be
noted that when CFIm25 was knocked out in Col1a1-expressing cells
before treatment with bleomycin, pulmonary inflammation was further
enhanced in mice with CFIm25-depleted fibroblasts. This possibly oc-
curs by activation of pathways, including JAK/STAT3, which are en-
gaged in inflammation [81]. IL-6, via its receptor IL-6R, is known to
activate STAT3 [33]. Moreover, it is possible that Wnt5A binds to the
FZD2 receptor, and thus phosphorylates STAT3, which regulates the
EMT in cancer [16]. IL6 and JAK2 and together with WNT5A and FZD2
all cause 3′-UTR shortening in CFIm25-knockdown cells, implicating
the STAT3 pathway in CFIm25-depleted cells. Furthermore, Col1a1-
CreER-CFIm25fl/fl probably triggers the depletion of CFIm25 in Col1a1-
expressing cells, including osteoblasts and odontoblasts, which can in-
fluence inflammation [26]. The observation that elimination of CFIm25
in Foxd1-expressing pericytes increases pulmonary fibrosis without any
impact on inflammation, suggests that depleting CFIm25 may have
different eff3cts in different cells [81].
Another study investigated the role of CFIm25 in vascular
remodeling in pulmonary hypertension (PH). The results showed that
decreased CFIm25 in pulmonary arterial smooth muscle cells resulted
in production of some ECM components including fibronectin, collagen,
laminin, syndecan and thrombospondin. This alteration in ECM com-
ponents through CFIm25 and the APA process, led to vascular re-
modeling as well as the enlarged right ventricles seen in PH [8,79].
Another function of CFIm25 is in psychiatric disease by changing
the expression of MeCP2 (methyl CpG binding protein 2). A relatively
small alteration in the amount of MeCP2 in the brain may result in
neuropsychiatric disease. It is reported that increased CFIm25 led to
elevated MeCP2 production, whereas normalization of CFIm25 levels
returned MeCP2 back to normal levels [14]. These results show that
although CFIm25 is one of the major mediators in the process of
shortening the transcripts of genes, other influential factors are
miRNAs, the distribution of MREs on transcripts, and the network of the
ceRNAs. However, among these factors, the key role is played by
miRNAs.
7. Conclusion
Global shortening of mRNAs through APA is an important me-
chanism that regulates gene expression. This process, which occurs
during enhanced cellular proliferation, needs to be further elucidated.
CFIm25 is a broad repressor of proximal poly (A) site usage and in case
of CFIm25 depletion, cell proliferation increases. Significant increases
in the expression of several known oncogenes, such as cyclin D1 have
been reported as a consequence of CFIm25 depletion. Certain genes can
escape the regulation of miRNA and other RBPs by truncating their 3′
UTRs, which leads to cell proliferation. Research shows that this pattern
of polyA tail truncation contributes to the development of diseases in-
cluding cancer. A significant number of all of genes have different
isoforms caused by variation in the 3′ UTRs. 3′ UTRs are involved in
nonsense mediated decay, AU-rich element mediated decay and mRNA
surveillance, miRNA-mediated decay, to name just a few. Regarding the
distribution of MREs, since the shortening of mRNA transcripts of tumor
suppressor genes causes the MREs to become more active, as well as the
shortening of their ceRNA partners. Eventually shortening the tran-
scripts of these competitors would increase the miRNA-mediated si-
lencing of tumor suppressor genes in cancer cells. Both the oncogenes
and the tumor suppressor genes will undergo shortening of the 3′UTR to
the benefit of cancer progression. This mechanism shows how the
Fig. 3. The operation of the ceRNA network. How mRNAs impact miRNAs is less well understood than how miRNAs impact mRNAs. (A) The association between
mRNAs and miRNAs can be reciprocal [66], so that the level of one mRNA can affect the level and activity of another mRNA. (B) Hence, RNA molecules can
communicate with each other via miRNA and miRNA MREs. The larger the number of shared MREs, the greater the level of ‘‘communication’’ and therefore co-
regulation. (C) The 3′ UTRs of RNA molecules contain MREs, which could function in cis to modulate the RNA molecule itself, but also probably in trans to modulate
levels of miRNAs and subsequently other RNAs.
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shortening of the 3′UTR of two different categories of genes in the
tumor leads to tumor progression.
Elucidating the mechanism by which restoration of CFIm25 influ-
ences proliferation and apoptosis in cancer cells requires further study.
The suppression of specific miRNAs (such as miR-181) may represent a
promising therapeutic strategy to restore the CFIm25-mediated reg-
ulation of proliferation and apoptosis. Moreover, the complex interplay
between alternative splicing, APA, and mRNA decay and the regulation
of metabolic enzymes (such as glutaminase) should be further ad-
dressed. Also, since it has been shown that CFIm25 disrupts the EMT
and thereby inhibits cancer cell migration and invasion, enhancing
CFIm25 may be a potential clinical approach for cancer treatment.
CFIm25 leads to extensive shortening of UTRs, and causally leads to
enhanced cellular proliferation and tumorigenicity, probably through
the up-regulation of growth promoting factors, such as cyclin D1. The
significance of UTRs in control of cell growth underlines the need for
additional research into the mechanism and regulation of APA, and its
potential links to other human diseases.
Collectively, further research is needed to investigate the interplay
between APA and the regulation of various CFIm25 targets (such as
miRNA) in clinical settings. New research will improve our under-
standing of cancer etiology and help us to work out new ways to pre-
vent and treat it.
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